AEON Biopharma (AEON) has provided an announcement.
AEON Biopharma, Inc. has notified holders of its public warrants that they must exercise their right to purchase shares of the company’s common stock by April 29, 2024, or the warrants will become void. The fair market value for redemption has been set at $7.6994 per share, and on a cashless basis, holders will receive approximately 0.2456 shares for each warrant exercised. Unexercised warrants after the deadline will only entitle holders to a redemption price of $0.10 per warrant.
For a thorough assessment of AEON stock, go to TipRanks’ Stock Analysis page.